Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
4.9
Journals
Marine Drugs
Special Issues
Selected Papers from the International Conference on Coastal Ecology and...
share announcement

Selected Papers from the International Conference on Coastal Ecology and Marine Biotechnology Dec. 8-10, 2016 Bangkok, Thailand

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (1 July 2017) | Viewed by 11836

Special Issue Editors

Dr. Antonio Trincone

E-Mail Website
Guest Editor
Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Comprensorio Olivetti, Edificio 70, Via Campi Flegrei 34, I-80078 Pozzuoli, Napoli, Italy
Interests: biocatalysis; marine enzymes; marine glycosidases; marine biotechnology; oligosaccharides
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Se-Kwon Kim

E-Mail Website
Guest Editor
Department of Marine Science & Convergence Engineering, Hanyang University, Gyeonggi-do 11558, Republic of Korea
Interests: marine natural products; marine biotechnology, marine algae; anti-oxidant; anti-HIV; Anti-cancer; anti-allergy; anti-inflammation; marine cosmeceuticals; nutraceuticals and pharmaceuticals
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The International Conference on Coastal Ecology and Marine Biotechnology is organized by Asia-Pacific Association of Science, Engineering and Technology (APASET), will be held in Bangkok, Thailand from 8–10 December, 2016. The meeting will bring together the international scientific community and many segments of the biotech industry to provide a platform for exchanging ideas in marine biotechnology, coastal ecology and applications.

This Special Issue will host contributions to the conference related to the marine biotechnology aspects of the conference. In particular, marine microbiology and biotechnology, including genomics and proteomics of marine organisms and marine metagenomics will be expected in "Tools and Methods in Marine Biotechnology", while all aspects related to marine biomolecules are included in "Marine Resource: Research and Applications".

The conference will cover both the basic science, as well as its applications.

Program Chair of the Conference Dr. Se-Kwon Kim and Dr. A. Trincone of the scientific committee organized this Special Issue of Marine Drugs dedicated to this conference, and kindly invite you to participate to this Special Issue.

Dr. Antonio Trincone
Prof. Dr. Se-Kwon Kim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

1274 KiB  
Article
Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models
by Youying Zhang, Tian Meng, Ling Zuo, Yu Bei, Qihao Zhang, Zhijian Su, Yadong Huang, Jiyan Pang, Qi Xiang and Hongtu Yang
Mar. Drugs 2017, 15(6), 163; https://doi.org/10.3390/md15060163 - 3 Jun 2017
Cited by 38 | Viewed by 5534
Abstract
The goal of this study was to examine the effects of xyloketal B on nonalcoholic fatty liver disease (NAFLD) and to explore the molecular mechanisms underlying its effects in both in vivo and in vitro models. We discovered an association between xyloketal B [...] Read more.
The goal of this study was to examine the effects of xyloketal B on nonalcoholic fatty liver disease (NAFLD) and to explore the molecular mechanisms underlying its effects in both in vivo and in vitro models. We discovered an association between xyloketal B and the sterol regulatory element-binding protein-1c (SREBP-1c) signaling pathway, which is related to lipid metabolism. Mice were dosed with xyloketal B (5, 10 and 20 mg/kg/d) and atorvastatin (15 mg/kg/d) via intraperitoneal injection once daily for 40 days after being fed a high fat diet plus 10% high fructose liquid (HFD+HFL) for 8 weeks. Xyloketal B significantly improved HFD+HFL-induced hepatic histological lesions and attenuated lipid and glucose accumulation in the blood as well as lipid accumulation in the liver. Xyloketal B increased the expression of CPT1A, and decreased the expression of SREBP-1c and its downstream targeting enzymes such as ACC1, ACL, and FAS. Xyloketal B also significantly reduced lipid accumulation in HepG2 cells treated with free fatty acids (FFAs). These data suggested that xyloketal B has lipid-lowering effects via the SREBP-1c pathway that regulate lipid metabolism. Thus, targeting SREBP-1c activation with xyloketal B may be a promising novel approach for NAFLD treatment. Full article
(This article belongs to the Special Issue Selected Papers from the International Conference on Coastal Ecology and Marine Biotechnology Dec. 8-10, 2016 Bangkok, Thailand)
►▼ Show Figures

Figure 1

1199 KiB  
Article
Pharmacophore-Based Virtual Screening of Novel Inhibitors and Docking Analysis for CYP51A from Penicillium italicum
by Yongze Yuan, Rui Han, Qianwen Cao, Jinhui Yu, Jiali Mao, Tingfu Zhang, Shengqiang Wang, Yuhui Niu and Deli Liu
Mar. Drugs 2017, 15(4), 107; https://doi.org/10.3390/md15040107 - 5 Apr 2017
Cited by 10 | Viewed by 5591
Abstract
Sterol 14α-demethylases from Cytochrome P450 family (CYP51s) are essential enzymes in sterol biosynthesis and well-known as the target of antifungal drugs. The 3D structure of CYP51A from Penicillium italicum (PiCYP51A) was constructed through homology modeling based on the crystal structure of human CYP51A [...] Read more.
Sterol 14α-demethylases from Cytochrome P450 family (CYP51s) are essential enzymes in sterol biosynthesis and well-known as the target of antifungal drugs. The 3D structure of CYP51A from Penicillium italicum (PiCYP51A) was constructed through homology modeling based on the crystal structure of human CYP51A (PDB: 3LD6). Molecular dynamics (MD) simulation was operated to relax the initial model and followed by quality assessment using PROCHECK program. On the basis of the docking information on the currently available CYP51s with the patent demethylase inhibitors (DMIs), pharmacophore-based virtual screening combined with docking analysis was performed to pick out twelve new compounds from ZINC database. Six hits revealed in the ligand database suggested potential ability to inhibit PiCYP51A. Compared to patent fungicide triazolone, the top three lead compounds had similar or higher affinity with the target enzyme, and accordingly, exhibited comparable or lower EC50 values to P. italicum isolates. The results could provide references for de novo antifungal drug design. Full article
(This article belongs to the Special Issue Selected Papers from the International Conference on Coastal Ecology and Marine Biotechnology Dec. 8-10, 2016 Bangkok, Thailand)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop